Valion Bio (VBIO) EBITDA (2021 - 2025)

Valion Bio has reported EBITDA for 5 years, with the latest figure at -$2.5 million in Q3 2025.

• On a quarterly basis, EBITDA fell 73.52% year-over-year to -$2.5 million in Q3 2025; TTM through Sep 2025 was -$7.4 million, a 15.32% decrease from a year earlier, with the FY2024 full-year figure at -$5.7 million, up 31.34% from the prior year.
• EBITDA was -$2.5 million for Q3 2025 at Valion Bio, down from -$1.9 million in the prior quarter.
• The five-year high for EBITDA was -$1.1 million in Q2 2021, with the low at -$3.0 million in Q2 2022.
• Average EBITDA over 5 years is -$1.9 million, with a median of -$1.9 million recorded in 2025.
• The sharpest annual moves came in 2022 and 2024: EBITDA slumped 186.07% in 2022, then jumped 40.42% in 2024.
• Over 5 years, EBITDA stood at -$2.3 million in 2021, then advanced by 1.57% to -$2.3 million in 2022, then increased by 0.53% to -$2.2 million in 2023, then soared by 33.91% to -$1.5 million in 2024, then tumbled by 67.43% to -$2.5 million in 2025.
• The last three EBITDA figures came in at -$2.5 million (Q3 2025), -$1.9 million (Q2 2025), and -$1.5 million (Q1 2025), per Business Quant data.